CRSP
Price
$53.50
Change
-$0.71 (-1.31%)
Updated
Jan 16, 04:59 PM (EDT)
Capitalization
5.17B
32 days until earnings call
Intraday BUY SELL Signals
NTLA
Price
$12.48
Change
+$0.61 (+5.14%)
Updated
Jan 16, 04:59 PM (EDT)
Capitalization
1.37B
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRSP vs NTLA

Header iconCRSP vs NTLA Comparison
Open Charts CRSP vs NTLABanner chart's image
CRISPR Therapeutics AG
Price$53.50
Change-$0.71 (-1.31%)
Volume$14.41K
Capitalization5.17B
Intellia Therapeutics
Price$12.48
Change+$0.61 (+5.14%)
Volume$81.88K
Capitalization1.37B
CRSP vs NTLA Comparison Chart in %
View a ticker or compare two or three
VS
CRSP vs. NTLA commentary
Jan 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and NTLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 17, 2026
Stock price -- (CRSP: $54.21 vs. NTLA: $11.87)
Brand notoriety: CRSP and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 76% vs. NTLA: 118%
Market capitalization -- CRSP: $5.17B vs. NTLA: $1.37B
CRSP [@Biotechnology] is valued at $5.17B. NTLA’s [@Biotechnology] market capitalization is $1.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 2 bearish.
  • NTLA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than NTLA.

Price Growth

CRSP (@Biotechnology) experienced а -3.88% price change this week, while NTLA (@Biotechnology) price change was +12.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.08%. For the same industry, the average monthly price growth was +4.20%, and the average quarterly price growth was +43.03%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 17, 2026.

NTLA is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (-0.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.17B) has a higher market cap than NTLA($1.38B). NTLA YTD gains are higher at: 32.036 vs. CRSP (3.375). NTLA has higher annual earnings (EBITDA): -466.25M vs. CRSP (-555.73M). CRSP has more cash in the bank: 1.92B vs. NTLA (511M). NTLA has less debt than CRSP: NTLA (98M) vs CRSP (211M). NTLA has higher revenues than CRSP: NTLA (57.5M) vs CRSP (35M).
CRSPNTLACRSP / NTLA
Capitalization5.17B1.38B376%
EBITDA-555.73M-466.25M119%
Gain YTD3.37532.03611%
P/E RatioN/AN/A-
Revenue35M57.5M61%
Total Cash1.92B511M375%
Total Debt211M98M215%
FUNDAMENTALS RATINGS
CRSP vs NTLA: Fundamental Ratings
CRSP
NTLA
OUTLOOK RATING
1..100
1120
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
5853
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for CRSP (73). This means that NTLA’s stock grew somewhat faster than CRSP’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that NTLA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as NTLA (97). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Price Growth Rating (53) in the Biotechnology industry is in the same range as CRSP (58). This means that NTLA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as NTLA (100). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPNTLA
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 17 days ago
88%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TGRHX6.900.09
+1.32%
Transamerica International Focus A
TGVNX27.550.31
+1.14%
TCW Relative Value Mid Cap N
WTRCX11.140.06
+0.54%
Nomura Core Equity Fund Class C
HILVX20.570.07
+0.34%
Harbor Large Cap Value Inv
VFWSX151.020.47
+0.31%
Vanguard FTSE All-Wld ex-US Idx Instl

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-4.71%
BEAM - CRSP
72%
Closely correlated
-9.49%
RXRX - CRSP
68%
Closely correlated
-4.33%
ABSI - CRSP
62%
Loosely correlated
-8.96%
PRME - CRSP
60%
Loosely correlated
-7.42%
NTLA - CRSP
59%
Loosely correlated
-1.25%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.25%
VCYT - NTLA
69%
Closely correlated
-3.42%
BEAM - NTLA
62%
Loosely correlated
-9.49%
CRSP - NTLA
59%
Loosely correlated
-4.71%
AXON - NTLA
55%
Loosely correlated
+1.27%
CDXS - NTLA
50%
Loosely correlated
N/A
More